Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Targovax ASA ( (GB:0RIS) ) has shared an update.
Circio Holding ASA has announced the conversion of convertible bonds into 3,931,847 new shares, increasing its share capital by NOK 2,359,108.20. This move is part of an investment agreement with Atlas Special Opportunities, LLC, and will result in a total share capital of NOK 56,845,650.60. The issuance of new shares is expected to strengthen Circio’s financial position and support its ongoing research and development efforts in RNA technology and cancer therapeutics.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced RNA technology for nucleic acid medicine. The company has created a unique circular RNA vector expression platform, circVec, which enhances protein expression significantly compared to traditional mRNA systems. Circio is also working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.
Average Trading Volume: 1,111,100
Current Market Cap: NOK63.39M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.